Cencora appoints Robert Sanchez to board Oct. 1
Sanchez’s director compensation includes quarterly cash payments and an equity award pro-rated from October 1, 2026, through Cencora’s 2027 annual meeting.
Rhea-AI Filing Summary
Cencora, Inc. (COR) appointed Robert E. Sanchez as an independent director, effective October 1, 2026. The appointment increases the board from ten to eleven members. Sanchez is executive chair of Ryder System and previously served as its chair and CEO until his retirement in March 2026. He also serves on the board of Texas Instruments and as a trustee of the University of Miami.
Sanchez will receive the same benefits and compensation as other non-employee directors. Cash compensation is paid quarterly, and his annual equity award will be pro-rated for the period beginning October 1, 2026, and ending on the date of Cencora’s 2027 Annual Meeting of Stockholders. At the time of the announcement, he had not been named to a board committee.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
independent director regulatory
non-employee director financial
pro-rated financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is Cencora (COR)’s new board director, and when does he join?
What compensation will Robert E. Sanchez receive as a Cencora director?
Does Robert E. Sanchez have a committee assignment at Cencora?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in its charter)
Commission File Number:
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
| New York Stock Exchange ( | ||
| New York Stock Exchange ( | ||
| New York Stock Exchange ( |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Director Appointment
On September 24, 2026, the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Robert E. Sanchez to serve on the Board (the “Appointment”), effective October 1, 2026 (the “Effective Date”). In connection with the Appointment, the Board increased from ten to eleven members in accordance with the Company’s Amended and Restated Bylaws.
Mr. Sanchez will receive the same benefits and compensation as the other non-employee directors on the Board pursuant to the Company’s Compensation Policy for Non-Employee Directors, as described on pages 40 to 41 of the Definitive Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on January 22, 2026. Cash compensation is paid on a quarterly basis and the non-employee director annual equity award will be pro-rated for the period beginning on the Effective Date and ending on the date of the Company’s 2027 Annual Meeting of Stockholders.
There are no arrangements or understandings between Mr. Sanchez and any other persons pursuant to which Mr. Sanchez was appointed as a director. There are no family relationships between Mr. Sanchez and any director or executive officer of the Company, and the Company has not entered into any transactions with Mr. Sanchez that would require disclosure under Item 404(a) of Regulation S-K. At this time, Mr. Sanchez has not been named to serve on any committees of the Board.
Item 7.01. Regulation FD Disclosure.
On September 25, 2026, the Company issued a news release announcing the Appointment. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information provided herein shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number |
Description | |
| 99.1 | Press Release dated September 25, 2026. | |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cencora, Inc. | ||
| September 25, 2026 | By: | /s/ Elizabeth S. Campbell |
| Name: Elizabeth S. Campbell | ||
| Title: Executive Vice President and Chief Legal Officer | ||
Exhibit 99.1
| Press Release | |
 |
CENCORA ELECTS ROBERT E. SANCHEZ TO ITS BOARD OF DIRECTORS
CONSHOHOCKEN, PA, September 25, 2026 — Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.
Mr. Sanchez is the Executive Chair of Ryder System, Inc., where he previously served as Chair and Chief Executive Officer until his retirement in March 2026. Prior to being appointed CEO in 2013, Mr. Sanchez spent two decades with Ryder serving in roles of increasing responsibility including President and Chief Operating Officer, President of Global Fleet Management Solutions and Executive Vice President and Chief Financial Officer.
“Robert’s experience as a public-company CEO, including his deep understanding of logistics and supply chains, will complement the Board’s skill set as we support Cencora’s pharmaceutical-centric strategy. His appointment reflects the Board’s ongoing commitment to leaders whose perspectives will further the company’s growth ambitions,” said Mark Durcan, Chair of Cencora’s Board of Directors.
“Throughout his career at Ryder, Mr. Sanchez has shaped a thoughtful approach to strategy, execution and long-term value creation. His breadth of experience across operations, finance and technology will add valuable insight as we advance Cencora’s priorities and drive sustained growth,” said Robert P. Mauch, President and Chief Executive Officer of Cencora.
Mr. Sanchez currently serves on the Board of Directors of Texas Instruments and as a Trustee of the University of Miami. Mr. Sanchez holds a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Bachelor of Science from the University of Miami.
About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #16 on the Global Fortune 500 with more than $300 billion in annual revenue. Learn more at investor.cencora.com
Contact:
Melissa O’Brien
Vice President, Investor Relations
melissa.obrien@cencora.com